Increlex

Mecasermin, the active ingredient in Increlex, is an insulin-like growth factor‑1 (IGF‑1) analog presented as a subcutaneous formulation for subcutaneous use. It is indicated for children with severe primary IGF‑1 deficiency or growth hormone gene deletion, helping to promote linear growth.

GNH USA supplies Increlex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Increlex is used to address growth failure related to the IGF‑1 pathway in pediatric patients.

- Severe primary IGF‑1 deficiency: promotes linear growth in children lacking endogenous IGF‑1. - Growth hormone gene deletion: supports growth in children with absent GH production.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially when administered without adequate carbohydrate intake. - Injection site reactions: redness, swelling, or pain at the injection site. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Edema: peripheral swelling, often mild. - Lipodystrophy: changes in subcutaneous fat distribution.

Serious or Rare Side Effects: - Intracranial hypertension: signs include headache, visual disturbances, or papilledema. - Slipped capital femoral epiphysis: hip pain and limited motion. - Severe hypoglycemia: seizures or loss of consciousness. - Anaphylactic reactions: rash, breathing difficulty, or swelling of face and throat. - Tumor progression: accelerated growth of pre‑existing malignancies. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood glucose: check for hypoglycemia, especially after dose changes. - Assess IGF‑1 levels: ensure appropriate dosing and response. - Screen for intracranial hypertension: watch for persistent headaches or visual changes. - Evaluate for orthopedic complications: monitor for signs of slipped capital femoral epiphysis. - Avoid use in active malignancy: IGF‑1 may stimulate tumor growth. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mecasermin may interact with other agents that affect glucose metabolism or growth pathways.

Major Interactions (Avoid): - Insulin: combined use can cause severe hypoglycemia. - Oral hypoglycemic agents: increased risk of low blood sugar. - Growth hormone therapy: potential antagonistic effects on IGF‑1 signaling. - High‑dose glucocorticoids: may reduce the efficacy of IGF‑1.

Moderate Interactions (Monitor Closely): - Diazoxide: may blunt the hypoglycemic effect of Mecasermin. - Beta‑blockers: can mask hypoglycemia symptoms. - CYP450 inducers: may alter metabolic clearance of concomitant drugs, requiring dose adjustments.